AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ ~~(~~SEQ ID NO:52~~)~~;

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ ~~(~~SEQ ID NO:52~~)~~, lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~;

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~; or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said isolated nucleic acid is more highly expressed in normal skin tissue compared to melanoma, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal skin tissue compared to melanoma.

2. **(Currently Amended)** The isolated nucleic acid of Claim 1 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ ~~(~~SEQ ID NO:52~~)~~;

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ ~~(~~SEQ ID NO:52~~)~~, lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~;

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51~~)~~; or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said isolated nucleic acid is more highly expressed in normal skin tissue compared to melanoma, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal skin tissue compared to melanoma.

3. **(Currently Amended)** The isolated nucleic acid of Claim 1 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52~~)~~;

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52~~)~~, lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51~~)~~;

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51~~)~~; or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said isolated nucleic acid is more highly expressed in normal skin tissue compared to melanoma, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal skin tissue compared to melanoma.

4. **(Currently Amended)** The isolated nucleic acid of Claim 1 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52~~)~~;

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51);

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51); or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said isolated nucleic acid is more highly expressed in normal skin tissue compared to melanoma, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal skin tissue compared to melanoma.

5. **(Currently Amended)** The isolated nucleic acid of Claim 1 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52);

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51);

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51); or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said isolated nucleic acid is more highly expressed in normal skin tissue compared to melanoma, or wherein said isolated nucleic acid encodes a polypeptide that is more highly expressed in normal skin tissue compared to melanoma.

6. **(Currently Amended)** An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52 (~~SEQ ID NO:52~~)~~;

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52 (~~SEQ ID NO:52~~)~~, lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~;

~~(f)~~ (d) the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~; or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245.

7. **(Currently Amended)** The isolated nucleic acid of Claim 6 comprising a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52 (~~SEQ ID NO:52~~)~~.

8. **(Currently Amended)** The isolated nucleic acid of Claim 6 comprising a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52 (~~SEQ ID NO:52~~)~~, lacking its associated signal peptide.

9. **Canceled**

10. **Canceled**

11. **(Currently Amended)** The isolated nucleic acid of Claim 6 comprising the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~.

12. **(Currently Amended)** The isolated nucleic acid of Claim 6 comprising the full-length coding sequence of the nucleic acid sequence of ~~shown in Figure 51 (~~SEQ ID NO:51~~)~~.

13. **(Original)** The isolated nucleic acid of Claim 6 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203245.

14. **(Currently Amended)** An isolated nucleic acid that hybridizes under stringent conditions to:

(a) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52);

(b) a nucleic acid sequence encoding the polypeptide of ~~shown in Figure 52~~ (SEQ ID NO:52), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 52 (SEQ ID NO:52), lacking its associated signal peptide;~~

~~(e)~~ (c) the nucleic acid sequence of ~~shown in Figure 51~~ (SEQ ID NO:51);

~~(f)~~ (d) the full-length coding sequence of the nucleic acid of ~~sequence shown in Figure 51~~ (SEQ ID NO:51); or

~~(g)~~ (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203245;

wherein said stringent conditions comprise 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

15. **Canceled**

16. **(Original)** The isolated nucleic acid of Claim 14 which is at least 10 nucleotides in length.

17. **(Original)** A vector comprising the nucleic acid of Claim 1.

18. **(Original)** The vector of Claim 17, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

19. **(Original)** A host cell comprising the vector of Claim 17.

20. **(Currently Amended)** The host cell of Claim 19, wherein said cell is a ~~CHO~~ Chinese Hamster Ovary cell, an E. coli or a yeast cell.

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.